According to a new mouse study, cancer drugs could be helpful in treating Alzheimer's disease. The study has been published in the journal Annals of Neurology.

The drug, AZD05030, has been developed by researchers at the Yale School of Medicine. The drug didn't work in the treatment of solid tumors. But according to Astra Zenca, the official maker of the drug, they performed human trials for testing the efficacy of the drug in Alzheimer's patients.

According to Stephen M. Strittmatter, the Vincent Coates Professor of Neurology and senior author of the study, "With this treatment, cells under bombardment by beta amyloid plaques show restored synaptic connections and reduced inflammation, and the animal's memory, which was lost during the course of the disease, comes back".

Scientists are working to find out more regarding the Alzheimer's disease as they are developing new drugs and treatments, which could help deal with in the neurodegenerative health issue. The new drug basically blocks one of the molecular steps, which causes the disease. It also blocks activation the enzyme FYN that causes the loss of synaptic connections between brain cells.

According to Christopher P. Austin, MD, director of NIH's National Center for Advancing Translational Sciences (NCATS), which sponsored the work, their New Therapeutic Uses program model is validated by the speed with which the drug moved to human trials and it also helps their mission treat more patients more quickly.

According to senior author of the study, Stephen M. Strittmatter, in this treatment, cells under bombardment by beta amyloid plaques leads to reduced inflammation and restored synaptic connections, and memory of the animal, lost during the disease is restored.